Notably, emerging data suggest that the ratio of leptin-to-adiponectin (L/A) levels may be a better indicator of the risk of cardiovascular disease and mortality in CKD [27,28], as it holistically accounts for both pro-atherogenic leptin and anti-atherogenic adiponectin concentrations. Here, ADIPOQ is linked to chronic kidney disease.